-
-
Call more information
660-596-2224 -
Patients using the sumatriptan iontophoretic transdermal patch (Zecuity) to treat migraines could be burned or permanently scarred, warns the FDA. The agency says it has received a “large number” of reports of skin reactions associated with the patch since it went on the market in September 2015. The patch — battery-powered and wrapped around the […]
Read MoreAuthors: J. Lance Lichtor, M.D. et al Anesthesiology 6 2016, Vol.124, 1404-1407. Due to the potentially unforgiving nature of epiglottitis and supraglottitis, the clinician should have a firm understanding of the presentation, work up, and management of a patient presenting with worrisome symptoms. George Washington, the United States’ first president, 2 yr after leaving office on […]
Read MoreAuthors: Christopher Uhlig, M.D. et al Anesthesiology 6 2016, Vol.124, 1230-1245. Background: It is not known whether modern volatile anesthetics are associated with less mortality and postoperative pulmonary or other complications in patients undergoing general anesthesia for surgery. Methods: A systematic literature review was conducted for randomized controlled trials fulfilling following criteria: (1) population: adult patients undergoing general […]
Read MoreThe FDA has approved a buprenorphine implant as a maintenance treatment for opioid dependence. Probuphine, made up of four inch-long rods placed subdermally on the inside of the upper arm, is designed to deliver a steady dose of buprenorphine over a 6-month period. The implant is approved for patients who are already on low-to-moderate doses […]
Read MoreOpioids commonly are used for pain management in patients with osteoarthritis. However, a new study has found that reducing opioid use by half prior to surgery may lead to better functional outcomes. By Thomas G. Ciccone and Forest Tennant, MD, DrPH Interview with Kevin J. Bozic, MD, MBA Managing pain from knee or hip osteoarthritis (OA) is oftentimes […]
Read More